As PRA’s Chief Scientific Officer, Mr Thoelke provides corporate oversight and strategy for Scientific & Medical Affairs, Pharmacovigilance & Patient Safety, Therapeutic Centers of Excellence, Real World Data, Patient Access & Experience, Digital Health & Virtual Trials, and their integration into operational delivery. Mr Thoelke is an industry pioneer in the application of mobile first strategies, which integrate clinical trials and provide access directly to patients in both virtual and hybrid-virtual models. He emphasizes leveraging real world data, social insights, and patient connectivity to advance global drug development.